From Vaccine Vector to Oncomodulation: Understanding the Complex Interplay between CMV and Cancer

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Human cytomegalovirus (CMV) establishes lifelong, usually asymptomatic, infections.
• CMV infection drives significant antigen-specific T cell expansion.
• CMV is being explored as a vaccine platform for infectious diseases and cancer.

Purpose of the Study:

• To review the current literature on CMV-based vaccines for cancer.
• To identify key questions and challenges in developing CMV-based cancer vaccines.
• To propose a hypothesis regarding CMV's dual role in tumor progression.

Main Methods:

• Literature review of pre-clinical and clinical studies.
• Analysis of CMV's interaction with the tumor microenvironment.
• Synthesis of evidence on CMV's pro- and anti-tumorigenic effects.

Main Results:

• Pre-clinical data support CMV-based vaccines for infectious diseases, enhancing CD8+ T cell and antibody responses.
• Limited research exists on CMV-based cancer vaccines, with early mouse studies conducted.
• Evidence suggests human CMV is present in cancers and may influence tumor growth, with roles varying by model.
• Mechanisms of CMV's impact on tumor progression are not fully understood.

Conclusions:

• CMV-based vaccines hold potential, particularly for infectious diseases.
• Understanding CMV's complex interaction with the tumor microenvironment is crucial for cancer vaccine development.
• CMV's role in cancer may be context-dependent, influenced by viral location and activity within the tumor lesion.